(Q41506323)

1 October 2017

1 reference

title

Innovations in topical therapy (English)

1 reference

1 October 2017

Richter F

1

1 reference

1 October 2017

Scheppach W

series ordinal

2

1 reference

1 October 2017

publication date

1 March 1997

1 reference

Bailliere's clinical gastroenterology

1 October 2017

published in

1 reference

1 October 2017

volume

11

1 reference

1 October 2017

issue

1

1 reference

1 October 2017

page(s)

97-109

1 reference

An experiment to determine the active therapeutic moiety of sulphasalazine

1 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2897%2990056-7

7 January 2021

Long-term use of mesalamine enemas to induce remission in ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2897%2990056-7

7 January 2021

5-Aminosalicylic acid enemas: effective agent in maintaining remission in left-sided ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2897%2990056-7

7 January 2021

Topical treatment of ulcerative proctitis with lidocaine.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2897%2990056-7

7 January 2021

Treatment of refractory ulcerative colitis with cyclosporin enemas

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2897%2990056-7

7 January 2021

A double-blind clinical trial to compare the effects of 4-aminosalicylic acid to 5-aminosalicylic acid in topical treatment of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2897%2990056-7

7 January 2021

Retrograde spread of 5-aminosalicylic acid enemas in patients with active ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2897%2990056-7

7 January 2021

5-Aminosalicylic Acid as Enemas or Suppositories in Distal Ulcerative Colitis?

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2897%2990056-7

7 January 2021

Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2897%2990056-7

7 January 2021

Spread and distribution of 5-ASA colonic foam and 5-ASA enema in patients with ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2897%2990056-7

7 January 2021

Better quality of therapy with 5-ASA colonic foam in active ulcerative colitis. A multicenter comparative trial with 5-ASA enema

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2897%2990056-7

7 January 2021

Intermittent therapy with high-dose 5-aminosalicylic acid enemas for maintaining remission in ulcerative proctosigmoiditis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2897%2990056-7

7 January 2021

A steroid enema, budesonide, lacking systemic effects for the treatment of distal ulcerative colitis or proctitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2897%2990056-7

7 January 2021

Metronidazole in the treatment of chronic proctitis: a controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2897%2990056-7

7 January 2021

Retrograde spread of hydrocortisone containing foam given intrarectally in ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2897%2990056-7

7 January 2021

Comparative trial of sodium cromoglycate enemas with prednisolone enemas in the treatment of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2897%2990056-7

7 January 2021

Treatment of diversion colitis with short-chain-fatty acid irrigation

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2897%2990056-7

7 January 2021

Treatment of active distal ulcerative colitis with immunoglobulin G enemas

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2897%2990056-7

7 January 2021

Retrograde spreading of hydrocortisone enema in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2897%2990056-7

7 January 2021

Sucralfate enema in ulcerative rectosigmoid lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2897%2990056-7

7 January 2021

Plasma prednisolone levels and adrenocortical responsiveness after administration of prednisolone-21-phosphate as a retention enema

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2897%2990056-7

7 January 2021

Rectally administered prednisolone--evidence for a predominantly local action

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2897%2990056-7

7 January 2021

A randomised trial comparing mesalazine and prednisolone foam enemas in patients with acute distal ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2897%2990056-7

7 January 2021

Comparison of budesonide and 5-aminosalicylic acid enemas in active distal ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2897%2990056-7

7 January 2021

Combination therapy in active distal colitis--more studies are warranted.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2897%2990056-7

7 January 2021

Budesonide versus prednisolone retention enemas in active distal ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2897%2990056-7

7 January 2021

Intermittent therapy with high-dose 5-aminosalicylic acid enemas maintains remission in ulcerative proctitis and proctosigmoiditis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2897%2990056-7

7 January 2021

Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2897%2990056-7

7 January 2021

Therapeutic benefits from a poorly absorbed prednisolone enema in distal colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2897%2990056-7

7 January 2021

Review article: topical corticosteroids in inflammatory bowel disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2897%2990056-7

7 January 2021

Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2897%2990056-7

7 January 2021

Sulphasalazine retention enemas in ulcerative colitis: a double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2897%2990056-7

7 January 2021

Comparison of bismuth citrate and 5-aminosalicylic acid enemas in distal ulcerative colitis: a controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2897%2990056-7

7 January 2021

Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2897%2990056-7

7 January 2021

The colonic epithelium in ulcerative colitis: an energy-deficiency disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2897%2990056-7

7 January 2021

Treatment of distal ulcerative colitis (proctosigmoiditis) in relapse: comparison of hydrocortisone enemas and rectal hydrocortisone foam

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2897%2990056-7

7 January 2021

A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2897%2990056-7

7 January 2021

Treatment of distal ulcerative colitis with short-chain fatty acid enemas. A placebo-controlled trial. German-Austrian SCFA Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2897%2990056-7

7 January 2021

Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2897%2990056-7

7 January 2021

Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2897%2990056-7

7 January 2021

Topical treatment of distal ulcerative colitis with 4-amino-salicylic acid enemas

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2897%2990056-7

7 January 2021

Short-chain fatty acid enemas: a cost-effective alternative in the treatment of nonspecific proctosigmoiditis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2897%2990056-7

7 January 2021

Topical treatment of ulcerative colitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2897%2990056-7

7 January 2021

5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2897%2990056-7

7 January 2021

Treatment of ulcerative colitis with local hydrocortisone

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2897%2990056-7

7 January 2021

Short-chain fatty acid topical treatment in distal ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2897%2990056-7

7 January 2021

Quantitative distribution of radiolabeled 5-aminosalicylic acid enemas in patients with left-sided ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2897%2990056-7

7 January 2021

Double-blind, placebo-controlled evaluation of 5-ASA suppositories in active distal proctitis and measurement of extent of spread using 99mTc-labeled 5-ASA suppositories

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2897%2990056-7

7 January 2021

10.1016/S0950-3528(97)90056-7

Identifiers

DOI

1 reference

1 October 2017

1 reference